EDTA TREATMENT OF INTERMITTENT CLAUDICATION - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

被引:63
|
作者
GULDAGER, B
JELNES, R
JORGENSEN, SJ
NIELSEN, JS
KLAERKE, A
MOGENSEN, K
LARSEN, KE
REIMER, KE
REIMER, E
HOLM, J
OTTESEN, S
机构
[1] CENT HOSP HILLEROD,DEPT SURG,HILLEROD,DENMARK
[2] SKEJBY UNIV HOSP,DEPT SURG,AARHUS,DENMARK
[3] SLAGELSE HOSP,DEPT SURG,SLAGELSE,DENMARK
[4] AALBORG HOSP,DEPT VASC SURG V,DK-9000 AALBORG,DENMARK
[5] BISPEBJERG HOSP,DEPT SURG L,DK-2400 COPENHAGEN,DENMARK
[6] KOLDING CTY HOSP,DEPT SURG,KOLDING,DENMARK
[7] GENTOFE UNIV HOSP,DEPT SURG,COPENHAGEN,DENMARK
关键词
ATHEROSCLEROSIS; CHELATION THERAPY; ETHYLENEDIAMINE-TETRAACETICACID; INTERMITTENT CLAUDICATION;
D O I
10.1111/j.1365-2796.1992.tb00533.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A double-blind, randomized multicentre study was undertaken to evaluate the possible effect of chelation treatment with ethylenediamine-tetraacetic acid (EDTA) in patients with severe intermittent claudication. A total of 153 patients received 20 intravenous infusions of either 3 g Na2EDTA or placebo during a period of 5-9 weeks. Vitamin, mineral and trace element supplements were administered orally. The changes observed in the pain-free and maximal walking distances, measured on a treadmill, were similar in the two groups. During the 3-month (n = 149) and 6-month (n = 123) follow-up period, no long-term therapeutic effect of EDTA could be demonstrated. The ankle-brachial blood pressure index remained unchanged throughout the study period. This study failed to demonstrate any effect of EDTA chelation treatment in intermittent claudication.
引用
收藏
页码:261 / 267
页数:7
相关论文
共 50 条
  • [1] Treatment of intermittent claudication with mesoglycan - A placebo-controlled, double-blind study
    Nenci, GG
    Gresele, P
    Ferrari, G
    Santoro, L
    Gianese, F
    THROMBOSIS AND HAEMOSTASIS, 2001, 86 (05) : 1181 - 1187
  • [3] KETANSERIN IN INTERMITTENT CLAUDICATION - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY
    CLEMENT, DL
    DUPREZ, D
    VANWASSENHOVE, A
    BRUSSELMANS, F
    INTERNATIONAL ANGIOLOGY, 1989, 8 (02) : 92 - 96
  • [4] PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL OF KETANSERIN IN TREATMENT OF INTERMITTENT CLAUDICATION
    DECREE, J
    GEUKENS, H
    LEEMPOELS, J
    VERHAEGEN, H
    LANCET, 1984, 2 (8406): : 775 - 779
  • [5] DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF BUFLOMEDIL IN INTERMITTENT CLAUDICATION
    FONSECA, V
    MIKHAILIDIS, DP
    BARRADAS, MA
    JEREMY, JY
    GRACEY, L
    DANDONA, P
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1988, 8 (05) : 377 - 381
  • [6] RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF KETANSERIN IN TREATMENT OF INTERMITTENT CLAUDICATION
    WALDEN, R
    BASS, A
    RABI, I
    ADAR, R
    JOURNAL OF CARDIOVASCULAR SURGERY, 1991, 32 (06): : 737 - 740
  • [7] A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
    Castaño, G
    Más, R
    Roca, J
    Fernández, L
    Illnait, J
    Fernández, JC
    Selman, E
    ANGIOLOGY, 1999, 50 (02) : 123 - 130
  • [8] Sulodexide in the treatment of intermittent claudication - Results of a randomized, double-blind, multicentre, placebo-controlled study
    Coccheri, S
    Scondotto, G
    Agnelli, G
    Palazzini, E
    Zamboni, V
    EUROPEAN HEART JOURNAL, 2002, 23 (13) : 1057 - 1065
  • [9] Randomized double-blind placebo-controlled crossover study of caffeine in patients with intermittent claudication
    Momsen, A. H.
    Jensen, M. B.
    Norager, C. B.
    Madsen, M. R.
    Vestersgaard-Andersen, T.
    Lindholt, J. S.
    BRITISH JOURNAL OF SURGERY, 2010, 97 (10) : 1503 - 1510
  • [10] A double-blind, placebo-controlled, phase II study of basic fibroblast growth factor in the treatment of intermittent claudication
    Cooper, LT
    Hirsch, AT
    Regensteiner, JG
    Casscells, SW
    CIRCULATION, 2000, 102 (18) : 373 - 374